This has been discussed ad nauseam. The FTC would object vociferously to having one company own both branded Copaxone and the obligate technology for making a generic version of Copaxone for the US market.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”